Solu-Cortef

Leukemia, B-Cell

Children's Oncology GroupPhase 2Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

2 Active assets in the Leukemia, B-Cell cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE St. Jude Children's Research Hospital	Phase 2	BB
PEGASPARGASE Children's Oncology Group	Phase 2	B
Inno-206 Children's Oncology Group	Phase 2	B
Cyclophosphamide Dana-Farber Cancer Institute	Phase 2	B
METHOTREXATE Children's Oncology Group	Phase 2	B

View all 22 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant

A

Indicative ·

81 / 100

childhood acute lymphoblastic leukemiaDormant

BB

Indicative ·

68 / 100

myelodysplastic syndromeDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.